OliX Pharmaceuticals Announces IND Submission to U.S. FDA to Evaluate Safety and Tolerability of OLX10212 in Phase 1 Clinical Trial

SUWON, South Korea--(BUSINESS WIRE)-- #AMD--OliX Pharmaceuticals announced the submission of an IND application of OLX10212 for the treatment of age-related macular degeneration to the FDA.